Description:  The FDA approved amivantamab  therapy for EGFR mutant NSCLC after progression on osimertinib. This approval is based on the phase III MARIPOSA-2 trial, with data first shared at ESMO 2023 in Madrid with a simultaneous publication in the Annals of Oncology. Lung Cancer Considered host Dr. Stephen Liu talks with two leading oncologists to learn more about how this therapy will be used by clinicians

Guest: Dr. Karen Reckamp, Professor of Medicine, Director of the Division of Medical Oncology, and Associate Director of Clinical Research at Cedars-Sinai Medical Center

Guest: Dr. William Nassib William, National Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil

Description: The FDA approved amivantamab therapy for EGFR mutant NSCLC after progression on osimertinib. This approval is based on the phase III MARIPOSA-2 trial, with data first shared at ESMO 2023 in Madrid with a simultaneous publication in the Annals of Oncology. Lung Cancer Considered host Dr. Stephen Liu talks with two leading oncologists to learn more about how this therapy will be used by clinicians Guest: Dr. Karen Reckamp, Professor of Medicine, Director of the Division of Medical Oncology, and Associate Director of Clinical Research at Cedars-Sinai Medical Center Guest: Dr. William Nassib William, National Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil

FDA Approval: MARIPOSA2, Amivantamab plus Chemotherapy after Osimertinib for EGFR NSCLC

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Science

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Share FDA Approval: MARIPOSA2, Amivantamab plus Chemotherapy after Osimertinib for EGFR NSCLC

Sign up to save your podcasts

FDA Approval: MARIPOSA2, Amivantamab plus Chemotherapy after Osimertinib for EGFR NSCLC

FDA Approval: MARIPOSA2, Amivantamab plus Chemotherapy after Osimertinib for EGFR NSCLC

More shows like Lung Cancer Considered

Freakonomics Radio

NEJM This Week

JAMA Clinical Reviews

Hidden Brain

The NPR Politics Podcast

ASCO Daily News

The Curbsiders Internal Medicine Podcast

Core IM | Internal Medicine Podcast

The Peter Attia Drive

Harrison's PodClass: Internal Medicine Cases and Board Prep

The Curious Clinicians

People I (Mostly) Admire

Conversations in Lung Cancer Research

The Weekly Show with Jon Stewart

Two Onc Docs